再鼎医药(ZLAB)今日盘前大跌5.01%,引发市场关注。该公司刚刚公布了2025年第二季度财务业绩和近期公司进展。
财报显示,再鼎医药2025年第二季度总收入为1.1亿美元,同比增长9%。尽管收入有所增长,公司仍未实现盈利。第二季度经营亏损为5,490万美元,同比收窄28%,调整后的经营亏损收窄37%至3,420万美元。公司表示正稳步迈向2025年第四季度实现盈利的目标。
尽管业绩有所改善,但投资者似乎对公司仍未实现盈利感到失望,导致股价下跌。此外,公司的主要产品则乐销售放缓,可能也引发了市场担忧。再鼎医药表示,将继续推进多个管线产品的研发和商业化,以期在未来实现更好的业绩表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.